title: [Protective role of antiretroviral treatment in the impairment of renal function in a cohort of human immunodeficiency virus patients].
abstract: OBJECTIVE
  To assess changes in renal function in a cohort of patients infected with the human immunodeficiency virus (HIV) and describe which factors are associated with deterioration.
  
  
  METHODS
  This was a prospective transversal study. The follow-up period was 12 months. Data were collected at baseline and one year including the glomerular filtration rate (GFR). We analyzed epidemiological data, comorbidities, CD4 lymphocytes, viral load, and AIDS status.
  
  
  RESULTS
  A total of 365 patients. Three hundred and thirteen (85%) were under highly active antiretroviral therapy (HAART); the median CD4 was 606 ± 314 and the CV was undetectable in 85%. At 1-year, we found a mean deterioration in the GFR of 9.7 ml/h. Eighty patients (21.8%) had a fall in GFR > 10 ml/h, while in 20 patients (5.8%) it was > 30 ml/h. An association was found regarding age, treatment with didanosine (DDI) and males (OR 1.89 95% CI 1.3 to 4.08, OR 2.3 95% CI 1.9 to 23 and OR 3.47 95% CI 1.6 to 14.20 respectively). We found a protective role of being under HAART (OR 0.54, 95% CI, 0.25 to 0.8).
  
  
  CONCLUSIONS
  There was a protective role of HAART in the deterioration of GFR of patients with HIV infection. Male gender, age and use of DDI were associated with worsening renal function. Tenofovir and protease inhibitors were not associated with further deterioration of renal function.
authors.affiliation: Servicio de Medicina Interna, Hospital Costa del Sol, Marbella, Málaga, España. luismr@hcs.es
authors.forename: Luis
authors.initials: L
authors.lastname: Mérida
authors.forename: Javier
authors.initials: J
authors.lastname: de la Torre
authors.forename: Julián
authors.initials: J
authors.lastname: Olalla
authors.forename: Mariam
authors.initials: M
authors.lastname: Noureddine
authors.forename: Alfonso
authors.initials: A
authors.lastname: del Arco
authors.forename: José Luis
authors.initials: JL
authors.lastname: Prada
authors.forename: Ana
authors.initials: A
authors.lastname: Aguilar
authors.forename: Javier
authors.initials: J
authors.lastname: García-Alegría
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D003430:Cross-Sectional Studies; D016049:Didanosine / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D015658:HIV Infections / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology*; D007674:Kidney Diseases / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D016049:Didanosine